收费全文 | 2360038篇 |
免费 | 196255篇 |
国内免费 | 4415篇 |
耳鼻咽喉 | 34264篇 |
儿科学 | 72464篇 |
妇产科学 | 62899篇 |
基础医学 | 332361篇 |
口腔科学 | 67511篇 |
临床医学 | 213982篇 |
内科学 | 463209篇 |
皮肤病学 | 47968篇 |
神经病学 | 199359篇 |
特种医学 | 95913篇 |
外国民族医学 | 888篇 |
外科学 | 359669篇 |
综合类 | 57088篇 |
一般理论 | 977篇 |
预防医学 | 189041篇 |
眼科学 | 55377篇 |
药学 | 177467篇 |
7篇 | |
中国医学 | 4690篇 |
肿瘤学 | 125574篇 |
2018年 | 24082篇 |
2016年 | 20504篇 |
2015年 | 23295篇 |
2014年 | 33734篇 |
2013年 | 51037篇 |
2012年 | 69054篇 |
2011年 | 72565篇 |
2010年 | 42648篇 |
2009年 | 40980篇 |
2008年 | 68978篇 |
2007年 | 73312篇 |
2006年 | 74172篇 |
2005年 | 72182篇 |
2004年 | 69481篇 |
2003年 | 67152篇 |
2002年 | 66310篇 |
2001年 | 112471篇 |
2000年 | 116329篇 |
1999年 | 97778篇 |
1998年 | 26203篇 |
1997年 | 23847篇 |
1996年 | 23780篇 |
1995年 | 24491篇 |
1994年 | 23063篇 |
1993年 | 21456篇 |
1992年 | 79283篇 |
1991年 | 76388篇 |
1990年 | 73546篇 |
1989年 | 70794篇 |
1988年 | 65783篇 |
1987年 | 64761篇 |
1986年 | 61297篇 |
1985年 | 58371篇 |
1984年 | 44150篇 |
1983年 | 37547篇 |
1982年 | 22795篇 |
1981年 | 20230篇 |
1980年 | 18932篇 |
1979年 | 41222篇 |
1978年 | 28904篇 |
1977年 | 24224篇 |
1976年 | 22683篇 |
1975年 | 23856篇 |
1974年 | 29532篇 |
1973年 | 27961篇 |
1972年 | 26167篇 |
1971年 | 24110篇 |
1970年 | 22704篇 |
1969年 | 21042篇 |
1968年 | 19093篇 |
Vaccination prevents severe morbidity and mortality from COVID-19 in the general population. The immunogenicity and efficacy of SARS-CoV-2 vaccines in patients with antibody deficiency is poorly understood.
ObjectivesCOVID-19 in patients with antibody deficiency (COV-AD) is a multi-site UK study that aims to determine the immune response to SARS-CoV-2 infection and vaccination in patients with primary or secondary antibody deficiency, a population that suffers from severe and recurrent infection and does not respond well to vaccination.
MethodsIndividuals on immunoglobulin replacement therapy or with an IgG less than 4 g/L receiving antibiotic prophylaxis were recruited from April 2021. Serological and cellular responses were determined using ELISA, live-virus neutralisation and interferon gamma release assays. SARS-CoV-2 infection and clearance were determined by PCR from serial nasopharyngeal swabs.
ResultsA total of 5.6% (n?=?320) of the cohort reported prior SARS-CoV-2 infection, but only 0.3% remained PCR positive on study entry. Seropositivity, following two doses of SARS-CoV-2 vaccination, was 54.8% (n?=?168) compared with 100% of healthy controls (n?=?205). The magnitude of the antibody response and its neutralising capacity were both significantly reduced compared to controls. Participants vaccinated with the Pfizer/BioNTech vaccine were more likely to be seropositive (65.7% vs. 48.0%, p?=?0.03) and have higher antibody levels compared with the AstraZeneca vaccine (IgGAM ratio 3.73 vs. 2.39, p?=?0.0003). T cell responses post vaccination was demonstrable in 46.2% of participants and were associated with better antibody responses but there was no difference between the two vaccines. Eleven vaccine-breakthrough infections have occurred to date, 10 of them in recipients of the AstraZeneca vaccine.
ConclusionSARS-CoV-2 vaccines demonstrate reduced immunogenicity in patients with antibody deficiency with evidence of vaccine breakthrough infection.
相似文献